Group 1 - The core point of the news is that Prasis (Shanghai) Pharmaceutical Technology Development Co., Ltd. experienced a stock price increase of 5.56%, reaching 57.00 CNY per share, with a total market capitalization of 4.503 billion CNY as of January 7 [1] - The company, established on February 22, 2013, and listed on May 17, 2022, focuses on technology development, transfer, consultation, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] Group 2 - From the perspective of fund holdings, the Chuangjin Hexin Fund has a significant position in Prasis, with its Chuangjin Hexin Health Mixed A Fund (013348) holding 121,000 shares, representing 4.56% of the fund's net value, making it the tenth largest holding [2] - The Chuangjin Hexin Health Mixed A Fund was established on January 26, 2022, with a current scale of 47.4529 million CNY, and has achieved a year-to-date return of 5.36%, ranking 833 out of 8,823 in its category [2] Group 3 - The fund manager of Chuangjin Hexin Health Mixed A Fund is Pi Jinsong, who has been in the position for 7 years and 71 days, managing assets totaling 900 million CNY, with the best fund return during his tenure being 92.69% and the worst being -49.36% [3]
普蕊斯股价涨5.56%，创金合信基金旗下1只基金重仓，持有12.1万股浮盈赚取36.3万元